Antibe Therapeutics (ATE) - Working towards a GI-safe NSAID drug

13:41 EDT 14 Jun 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Antibe Therapeutics: Antibe’s lead drug, ATB-346, combines a hydrogen sulfide (H2S)-emitting molecule with naproxen, an off-patent non-steroidal anti-inflammatory drug (NSAID). The firm plans to start a double-blinded Phase IIb osteoarthritis (OA) study in July 2018, with data expected in Q418. The trial’s efficacy results can build on recent Phase IIb gastrointestinal (GI) safety data and position Antibe well to seek ATB-346 partnerships or out-licensing deals.
ISIN: CA0370251039

Original Article: Antibe Therapeutics (ATE) - Working towards a GI-safe NSAID drug


More From BioPortfolio on "Antibe Therapeutics (ATE) - Working towards a GI-safe NSAID drug"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...